Full-Time

Head of Corporate Affairs

Posted on 5/19/2025

Deadline 5/30/25
Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior, Expert

Dublin, Ireland

Category
PR & Communications
Growth & Marketing
Requirements
  • Bachelor's degree and 10 years of Corporate Affairs and/or Operations experience OR Master's degree and 8 years of Corporate Affairs and/or Operations experience
  • Proven track record of successfully managing corporate reputation, employee engagement, and stakeholder relations
  • Strong understanding of the Irish media landscape and regulatory environment
  • Excellent written and verbal communication skills, with the ability to craft clear and compelling messages
  • Exceptional interpersonal and relationship-building skills
  • Ability to work effectively in a fast-paced, dynamic environment and manage multiple priorities
  • Proficiency in crisis communication and issue management
Responsibilities
  • Develop and implement strategies to enhance Amgen's reputation and profile in Ireland through media relations, public affairs, and stakeholder engagement
  • Design and execute initiatives to foster a positive and engaging work environment, ensuring employees are informed, motivated, and aligned with Amgen's mission and values
  • Build and maintain strong relationships with key stakeholders, including government officials, industry partners, and community leaders, to advance Amgen's interests and objectives
  • Leverage Amgen's expansion in Ireland to strengthen the company's brand presence and visibility, promoting its innovative biotechnology solutions and commitment to improving patient outcomes
  • Craft and deliver compelling messages that effectively communicate Amgen's goals, achievements, and values to both internal and external audiences
  • Develop and implement crisis communication plans to ensure timely and effective response to any potential issues that may impact Amgen's reputation
  • Manage a small team of 2-3 people
  • Work closely with other departments, including Human Resources, Legal, and Compliance, to ensure cohesive and effective communication strategies

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen stands out from competitors by reinvesting a large portion of its earnings into research and development, ensuring a strong pipeline of new treatments. The goal of Amgen is to improve patient care and outcomes through the discovery of effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

INACTIVE